lutetium Lu 177 anti-PD-L1 nanobody RAD204

{
  "id": "MLC-T-ONC-014910",
  "term": "lutetium Lu 177 anti-PD-L1 nanobody RAD204",
  "field": "Oncology and biomedicine",
  "definition": "A radioimmunoconjugate composed of a nanobody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and labeled with the beta-emitting radioisotope lutetium Lu 177, with potential imaging activity of PD-L1 tumor antigen expression during single-photon emission computerized tomography/computerized tomography (SPECT/CT) and with potential antineoplastic activity. Upon administration of lutetium Lu 177 anti-PD-L1 nanobody RAD204, the RAD204 moiety targets and binds to the PD-L1 expressed on certain tumor cells. Upon uptake and imaging, the radioisotope moiety can be visualized and the extent of PD-L1 expression can be assessed. Also, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PD-L1-expressing tumor cells. PD-L1, a transmembrane protein, is overexpressed on the surface of many cancer cell types.",
  "synonyms": [
    "177Lu-anti-PD-L1 single domain antibody RAD204",
    "177Lu-RAD-204",
    "177Lu-RAD204",
    "[Lu-177]RAD204",
    "lutetium Lu 177 anti-PD-L1 nanobody RAD-204",
    "lutetium Lu 177-labeled anti-PD-L1 nanobody RAD204"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-anti-pd-l1-nanobody-rad204/"
}